Companion Diagnostics Market Size By Product (Instruments, Consumables, Services), By Disease Indication (Breast cancer, Lung cancer, Colorectal Cancer, Skin cancer), By Technology (Immunohistochemistry, In Situ Hybridization, Polymerase Chain Reaction, Genetic Sequencing), By End-use (Hospitals, Diagnostic Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025

Published Date: Jul 2019  |  Report ID: GMI3972  |  Authors: Sumant Ugalmugle

Report Format: PDF   |   Pages: 110   |   Base Year: 2018




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Companion Diagnostics Market size was valued at USD 2 billion in 2018 and is expected to witness over 19% CAGR from 2019 to 2025. Growing incidences of adverse drug reactions will prove beneficial to the market growth. Adverse reactions worsen the patient’s existing condition and increase the morbidity and mortality rates. Patients on multiple dosages for various diseases at a time are susceptible to adverse drug reactions. Companion diagnostics (CDs) help doctors to identify patients at higher risk of side effects from certain medications and thus enable their prevention. 
 

Companion Diagnostics Market

Get more details on this report - Request Free Sample PDF
 

CDx further helps to adjust drug treatment to avoid hazardous repercussions and enhance clinical outcomes. Aforementioned advantages of complementary diagnostics in preventing the adverse effects will escalate its preference over the forecast period rendering significant positive impact on the market growth. 
 

Increasing prevalence of cancer across the globe will propel companion diagnostics industry over the analysis time frame. Cancer patients react differently to variety of drugs and consequently need personalized therapy. Companion diagnostics provide accurate information about the drug’s effectiveness and safety in different patient group. These benefits of companion diagnostics tests in the treatment of cancer will prove beneficial for the market demand. However, high cost of these tests may impede the market to some extent over the forecast period. 
 

Companion Diagnostics Market Report Coverage
Report Coverage Details
Base Year: 2018 Market Size in 2018: 2 Billion (USD)
Historical Data for: 2014 to 2018 Forecast Period: 2019 to 2025
Forecast Period 2019 to 2025 CAGR: 19% 2025 Value Projection: 6.5 Billion (USD)
Pages: 110 Tables, Charts & Figures: 110
Geographies covered (15): U.S., Canada, Germany, UK, France, Italy, Spain, India, China, Japan, Australia, Brazil, Mexico, South Africa, Saudi Arabia
Segments covered: Product, Disease Indication, Technology, End-use and Region
Companies covered (12): Abbott, Agilent Technologies, bioMérieux, Foundation Medicine, Illumina, MolecularMD (ICON), Myriad Genetic Laboratories, Johnson & Johnson, Qiagen, Roche, Thermo Fisher Scientific, Arup Laboratories
Growth Drivers:
  • Increasing drug diagnostic co-development
  • Improving regulatory scenario
  • Growing incidences of adverse drug reaction
  • Increasing prevalence of cancer globally
Pitfalls & Challenges:
  • High cost of companion diagnostics test in developing and underdeveloped regions

Get more details on this report - Request Free Sample PDF
 

Companion Diagnostics Market, By Product

Consumables segment is anticipated to witness around 19% CAGR through 2025. It includes reagent and media, that are required for assessment of patient’s reaction to the drug. Unlike instruments, consumables are frequently bought and have high replacement rate. They are consumed in large quantity to cater to increasing demand for companion diagnostics. 
 

Service segment was valued at USD 160 million in 2018 and is anticipated to show robust growth in the forecast timeframe. Outsourcing services enables healthcare facilities to emphasize on primary activities. Moreover, companies providing companion diagnostics services have expertise in the field and thus provides superior quality data. As companion diagnostics services enables healthcare professionals to provide superior quality therapy to patients by using personalized medications, its demand will rise over analysis period. 
 

By Disease Indication

Lung cancer application is projected to grow at more than 18.5% CAGR up to 2025. Substantial growth is attributed to increasing prevalence of cancer across the globe. Selection of effective treatment at early stages plays important role in the treatment of lung cancer. Companion diagnostics enables selection of treatment tailored considering individual needs.  Moreover, it also helps in avoiding adverse reactions throughout the course of treatment.
 

Skin cancer accounted for over 13% of overall companion diagnostics market revenue in 2018. Increasing prevalence of skin cancer due to adverse effects of cosmetics and excess exposure to harmful sun rays will surge demand for companion diagnostics tests. As per CDC, in 2016, 82,476 incidences of melanomas were reported in the U.S. alone. Companion diagnostics is playing pivotal role in assisting doctors to treat skin cancer patients.
 

Germany Companion Diagnostics Market By Disease Indication

Get more details on this report - Request Free Sample PDF

 

By Technology

In situ hybridization technology was valued at over USD 400 million in 2018. It uses amplifiable DNA as reporter molecule that produce multiple variants. In situ hybridization enables parallel analysis of multiple protein involved in tissues and cells making it possible to relate protein complex among individual’s cells. The technology is prominently used for fusion in non-small-cell lung cancer or detect amplification in breast cancer. It can detect known and novel fusion types and it is simple and easy to use with well designed probes.
 

Genetic sequencing market demand is anticipated to witness more than 20% CAGR through 2025. Next Generation Sequencing (NGS) is used for recognizing unknown genes for microbiome, cancer driver genes, hereditary diseases and also for clinical and research application purposes. Technologically advanced next generation sequencing methods enables in detecting fusions, mutations, microsatellite instability, copy number alterations, tumour mutation burden, etc. These features of genetic testing-based companion diagnostics assist in finding detailed genetic structure of an individual. 
 

By End-use

Hospitals had over 40% companion diagnostics market share in 2018 and it will expand enormously in the coming years. Increasing patient pool due to high prevalence of chronic disorders will prove beneficial for the segment growth. Hospitals incorporate technologically advanced companion diagnostics that enable physician to provide superior treatment to patient. Availability of developed infrastructure and skilled professionals in hospital increases patient’s preference towards hospitals, which is fuelling the market demand. 
 

Diagnostic laboratories segment is anticipated to witness around 19.5% growth over 2019 to 2025. Increasing awareness pertaining to benefits of early diagnosis have surged the demand for better and accurate diagnostic tests. Additionally, government funding for diagnostic tests to curb the burden of these diseases will benefit the segment growth. Moreover, availability of technological advanced devices for diagnosing specific type of cancer will enable healthcare professionals to provide patient with accurate data. 
 

By Region

North America companion diagnostics market size is estimated to witness more than 18% CAGR through 2025. Increasing prevalence of chronic diseases and growing geriatric population susceptible to these diseases is driving regional growth. Furthermore, high disposable income and affordability for companion diagnostics tests will render a significant positive impact regional market trend. 
 

Asia Pacific is anticipated to witness around 20.5% growth up to 2025. Growing patient pool will increase demand for superior quality diagnostic tests. Additionally, government initiatives for providing effective treatment to cancer patients is boosting APAC market growth. Furthermore, companies are taking initiatives and doing necessary alliances to demonstrate usefulness of companion diagnostics for curbing overall healthcare expenditure.
 

Asia Pacific Companion Diagnostics Market By Country

Get more details on this report - Request Free Sample PDF

 

Competitive Market Share

Some of the notable players operating in the companion diagnostics market share are Abbott, Agilent Technologies, bioMérieux, Foundation Medicine, Illumina, MolecularMD (ICON), Myriad Genetic Laboratories, Johnson & Johnson, Qiagen, Roche, Thermo Fisher Scientific and Arup Labortaories. Industry players are adopting strategies such as new product launches, collaborations and mergers and acquisitions to grab high revenue share.
 

Recent industry developments:

  • In April 2018, Bristol Myers Squibb and Illumina announced collaboration to develop and commercialize companion diagnostics for immunotherapy. This strategy aimed at developing new products to cater to demands of unmet needs of patients. This activity will help company to capture high revenue share.
     
  • In May 2015, AstraZeneca and Abbott entered into an agreement to develop companion diagnostic tests to identify patients suffering from severe asthma that can be benefitted with tralokinumab. Objective behind this strategy is to develop innovative product that will aid patients.
     

Companion diagnostics industry can be traced back to late 1990’s. In 1998, 16 oncology drugs were approved by FDA. Companion diagnostics for Herceptin was approved in 1998. Later, with extensive research undertaken by industry players, it started gaining momentum. Increasing chronic diseases such as cancer and neurology and adverse reactions has led into development of companion diagnostics technology. Currently the market players are taking initiatives to develop technologically advanced companion tests to aid treatment in improve patient’s life. This market has immense growth opportunities across the globe with large number of healthcare organizations generating huge amount of data annually that would assist researchers in R&D activities. The market is in booming phase and scenario is likely to remain so over the next decade.
 

Frequently Asked Questions (FAQ) :

The market size of companion diagnostics valued at USD 2 billion in 2018.
The industry share of companion diagnostics is projected to expand at more than 19% CAGR up to 2025.
North America is estimated to witness more than 18% CAGR through 2025, says this GMI report.
Companion diagnostics (CDs) is a way through which doctors can identify if a patient is prone to side effects caused by a certain drug, helping them adjust drug treatment to avoid hazardous repercussions.
Companion diagnostics help in the selection of adequate treatment that is tailored as per an individual’s need, further helping avoid adverse reactions throughout the course of cancer treatment.
Companies that offer companion diagnostics services are providing superior quality data, enabling healthcare professionals to offer efficient treatment to patients by using personalized medications.
According to reports, the hospitals segment accounts for a major share in the companion diagnostics industry, given to the admission of large number of patients suffering from chronic disorders in recent years.

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Premium Report Details

  • Published Date: Jul 2019
  • Pages: 110
  • Tables: 101
  • Charts / Figures: 9
  • Companies covered: 12
  • Countries covered: 15

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X